Top Movers

Company Announcements

Results of AGM

Related Companies

By LSE RNS

RNS Number : 9082E
ConvaTec Group PLC
11 May 2017
 

 

Result of Meeting

 

 

 

CONVATEC GROUP PLC - AGM

11 MAY 2017 - POLL RESULT

 

ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting today.  The results of the poll held in relation to the resolutions proposed at the meeting are set out below.

 

For (see note 2)

Against (see note 2)

Number of votes Withheld (see note 3)

Total Capital Instructed

Resolution

No of shares

%

No of Shares

%

1

Receive Annual Reports and Accounts

1,673,547,389

99.40

10,098,465

0.60

687,156

86.28%

2

Approve the Directors' Remuneration Report

1,649,328,475

97.94

34,666,528

2.06

338,007

86.29%

3

Approve the Directors' Remuneration Policy

1,674,663,195

99.45

9,331,808

0.55

338,007

86.29%

4

Elect Sir Christopher Gent as a director

1,676,668,959

99.58

7,122,017

0.42

542,034

86.28%

5

Elect Paul Moraviec as a director

1,659,821,604

98.56

24,175,399

1.44

336,007

86.29%

6

Elect Nigel Clerkin as a director

1,659,401,604

98.54

24,595,399

1.46

336,007

86.29%

7

Elect Steve Holliday as a director

1,677,375,498

99.61

6,621,505

0.39

336,007

86.29%

8

Elect Jesper Ovesen as a director

1,671,684,756

99.27

12,312,247

0.73

336,007

86.29%

9

Elect Rick Anderson as a director

1,679,301,346

99.72

4,695,657

0.28

336,007

86.29%

10

Elect Raj Shah as a director

1,646,289,348

98.06

32,613,689

1.94

5,429,973

86.03%

11

Elect Kasim Kutay as a director

1,655,528,107

98.31

28,468,896

1.69

336,007

86.29%

12

Appoint Deloitte LLP as auditors

1,683,082,895

99.95

914,108

0.05

336,007

86.29%

13

Authorise the Directors to agree the auditors' remuneration

1,681,391,151

99.85

2,605,452

0.15

336,407

86.29%

14

Authorise allotment of shares

1,529,102,605

90.93

152,583,558

9.07

2,646,847

86.18%

15

Authorise scrip dividend alternative

1,683,571,466

99.97

425,537

0.03

336,007

86.29%

16

Disapply pre-emption rights*

1,680,232,470

99.76

4,052,383

0.24

48,157

86.31%

17

Disapply pre-emption rights in connection with an acquisition or specified capital investment*

1,505,385,444

89.38

178,899,409

10.62

48,157

86.31%

18

Authorise purchase of own shares*

1,679,583,213

99.82

3,010,097

0.18

1,739,700

86.22%

19

Approve SAYE option scheme

1,680,350,606

99.77

3,932,247

0.23

50,157

86.31%

20

Approve US Employee Share Purchase Plan

1,683,935,777

99.98

347,076

0.02

50,157

86.31%

21

Authorise political donations and political expenditure

1,682,860,783

99.93

1,136,220

0.07

336,007

86.29%

22

Call general meetings on 14 days' notice*

1,662,315,089

98.71

21,681,914

1.29

336,007

86.29%

 

*Special Resolution

 

NOTES:

 

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes received.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue at 6.30pm on 9 May 2017 was 1,951,472,651 shares.  XX.XX% of voting capital was instructed.

 

 

 

 

 

About ConvaTec


ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

Enquiries

 

Analysts and Investors

 

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582

investorrelations@convatec.com

 

Media

 

Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226

Rebecca Fitchett, Finsbury                                                         +44 (0)207 251 3801

# # #

END


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGOKDDBNBKDDPD

Top of Page